What question did this study set out to answer?

Determine whether prior exposure to bispecific antibodies impairs the efficacy of subsequent chimeric antigen receptor T-cell therapy in patients with relapsed or refractory large B-cell lymphoma.

April 24, 2024BloodOpen Access

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

GCGilles CrochetCHU Dinant Godinne UCL Namur GIGloria IacoboniHebron University ACAudrey CouturierWayne State University

Discussion

Member takes

Implication

Retrospective study demonstrates preserved CAR T-cell efficacy in relapsed large B-cell lymphoma after bispecific antibody therapy, indicating viable sequential immunotherapy strategies.

Key Points

Determine whether prior exposure to bispecific antibodies impairs the efficacy of subsequent chimeric antigen receptor T-cell therapy in patients with relapsed or refractory large B-cell lymphoma.
Retrospective analysis of patients with relapsed or refractory large B-cell lymphoma who received CAR T-cell therapy following prior treatment with bispecific antibodies targeting distinct antigens.
Chimeric antigen receptor T cells maintained clinical efficacy in patients with relapsed or refractory large B-cell lymphoma despite previous exposure to bispecific antibodies.
Sequential therapy with bispecific antibodies targeting alternative antigens did not compromise the therapeutic performance of subsequent CAR T-cell infusions.

Cite This Study

Crochet et al. (2024) studied this question.

synapsesocial.com/papers/69fd85107f24f003e827117a https://doi.org/10.1182/blood.2024024526

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study demonstrates preserved CAR T-cell efficacy in relapsed large B-cell lymphoma after bispecific antibody therapy, indicating viable sequential immunotherapy strategies.

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider